Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

228 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-09-30

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intellectual disability (ID) moderate or severe affects about one child in 250, with 3000 to 4000 new cases each year. Chromosomal or molecular pathology causes are not identified in half of the cases by current techniques. Studies show that de novo mutations are common in many different genes. The "exome" approach by high-throughput sequencing (NGS) has emerged as the technique of choice for identifying and comparing the exome of the child to the parent. We wish to evaluate this approach and its contribution in the diagnostic management of 50 patients with DI seen in genetics in 6 CHU Great West. Genomics platform IBISA / Biogenouest will provide technological and bioinformatics support this project.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genome Sequencing Strategies for Genetics Diagnosis of Patients With Intellectual Disability

NCT04154891

Intellectual Disability

COMPLETED NA

Contribution of High Throughput RNA Sequencing Combined With Sequencing of Whole Genomes in the Diagnosis of Intellectual Disability

NCT03857997

Patients With Intellectual Disabilities Without an Obvious Clinical Diagnosis Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)

COMPLETED

Molecular Diagnosis of Syndromic or Isolated Severe Intellectual Disability Using Whole Exome Sequencing : a Pilot Study

NCT02862808

Severe Intellectual Disability

COMPLETED

Use of Long Read Genome Sequencing in Patients Suffering From Neurodevelopmental Troubles

NCT05643274

Genetic Disease Neurologic Disorder Developmental Delay Disorder +1 more

COMPLETED

Search for Phenotype-modifying Genes in Patients With Intellectual Disabilities.

NCT06706934

Intellectual Disability

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Intellectual Disability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with severe intellectual disability (IQ \<35 ) or moderate (IQ \<50) isolated or syndromic presentation but undiagnosed . The diagnosis is established during genetic counseling of a 6 CHU interregion
* Lack of family history ( parents). We are interested in this project to patients who do not have family history in order to increase the probability of identifying a de novo mutation . We do not however exclude the hypothesis for some patients a mechanism recessive autosomal or X-linked .
* Recruitment in 6 CHU HUGO . Patients are required to have been seen in genetics in a 6 CHU interregion . Molecular analyzes of the Fragile X syndrome and the CGH technique must be negative.
* Indication sequencing exomique adopted by the Scientific Committee. The Scientific Committee HUGODIMS project role to select patients whose DNA will be studied in order to optimize the chances of success for sequencing . This selection must take into account clinical parameters , but also genetic parameters ( potential inbreeding ) . The files will be selected by videoconferencing at the end of the monthly meeting of CLAD . The methodologist of the study will be invited to videoconferencing.
* specific consent obtained for the study.

Exclusion Criteria

* Parents patient with moderate or severe intellectual disability disagree with the preferred hypothesis of de novo mutation or recessive transmission mechanism.
* Form with known syndromic diagnosis can be targeted molecular studies (clinical signs).
* Cause molecular DI identified by targeted molecular analysis or CGH.
* Explicit refusal to participate in the study of the patient, parents, or one of the two parents.
* Any other indication that intellectual disability.
* The parents of the patient or the patient may be removed.

Eligible Sex

ALL

Accepts Healthy Volunteers

No